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Objective: To examine whether the distribution of prefrontal cortical thickness in patients with motor neuron
disease is normal or bimodal and how it compares to the normal population.
Methods: 158 patients with motor neuron disease (MND) and 86 healthy controls (HC) were enrolled in a
prospective, two-center study with a common structural MRI protocol. Cortical thickness measures were ex-
tracted for the prefrontal cortex, premotor cortex, motor cortex, and occipital cortex using FreeSurfer, adjusted
for age and sex, and tested for normality of distribution.
Results: Cortical thickness measures of the bilateral prefrontal, premotor, motor, and occipital cortex were
normally distributed in patients and healthy controls. MND-related cortical thinning was observed in the right
motor cortex (p=0.002), reﬂected in a signiﬁcantly higher proportion of MND cases being worse than −1
standard deviation of the healthy control mean: 29.1% in the right motor cortex (p=0.002). Cortical thinning of
the left motor cortex was a function of clinical phenotype and physical disability. Left prefrontal cortical
thickness was reduced in patients with additional cognitive and/or behavioural deﬁcits compared to MND pa-
tients without cognitive deﬁcits. Prefrontal, premotor, motor, and occipital cortical thickness was related to
patients' general cognitive abilities.
Conclusion: The study shows that prefrontal cortical thickness in MND is normally distributed but shifted to-
wards thinner cortex in MND patients with cognitive and/or behavioural impairment. The distribution of
thickness values did not indicate the assumption of a bimodal distribution although patients with comorbid
cognitive deﬁcits are more likely to suﬀer from prefrontal cortical thinning.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is characterised by the pro-
gressive loss of motor neurons. The heterogeneity in clinical phenotypes
is large, manifesting in sporadic or familial forms; varying degrees of
upper and lower motor neuron involvement; site of onset; and disease
progression (Swinnen and Robberecht, 2014). Up to 50% of the patients
show behavioural or cognitive impairment (Phukan et al., 2012), with
about 15% fulﬁlling the criteria for comorbid frontotemporal dementia
(FTD) (Montuschi et al., 2015; Phukan et al., 2012; Ringholz et al.,
2005).
Although there is compelling evidence for the co-occurrence of ALS
and FTD (DeJesus-Hernandez et al., 2011; Neumann et al., 2006;
Renton et al., 2011), it remains unclear if patients with ALS generally
are at risk of FTD or if only a subgroup. Previous studies have taken
advantage of magnetic resonance imaging techniques to compare grey
matter volume (Lillo et al., 2012a; Mioshi et al., 2013) and cortical
thickness (Schuster et al., 2014) across the spectrum of ALS and FTD.
Although these studies report an overlap in atrophy patterns, group
averages do not address how individual data points are distributed. FTD
comprises a variety of diﬀerent phenotypes, typically behavioural
variant FTD (bvFTD), semantic variant primary progressive aphasia (sv-
PPA) and non-ﬂuent variant PPA. Although all variants can occur with
ALS, it is the bvFTD phenotype that is most frequently observed in ALS-
FTD (Lillo et al., 2012b). One hallmark feature of bvFTD is involvement
of the frontal (and temporal) lobes, making prefrontal thinning a pos-
sible indicator for being at risk of FTD. This leads to the assumption that
if only a sub-group of patients with ALS were at risk of FTD, one
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prediction might be a bimodal distribution with respect to cortical
thickness in prefrontal regions — i.e. comprising a population with
thinning of the prefrontal cortex indicating risk of FTD and a population
with an identical distribution to the healthy population. On the other
hand, if the distribution were unimodal, the question arises as to
whether it would shift toward thinner cortex in ALS suggesting a more
general vulnerability to FTD. This study addressed these scenarios by
assessing the distribution of prefrontal cortex thickness (excluding
motor and premotor areas) in a large prospective, consecutive sample of
patients with motor neuron disease.
2. Methods
2.1. Participants
In this prospective, cross-sectional study two centres enrolled
n=158 patients with motor neuron disease (site 1: n=45, site 2:
n=113) between April 2011 and August 2014. In order to represent
the whole spectrum of diﬀerent motor neuron disease variants, the
following phenotypes were included (Chio et al., 2011): classical ALS
and bulbar phenotype (n=102, “classical ALS”); primary lateral
sclerosis (n=9, “PLS”); upper motor neuron dominant ALS (n=13,
“UMN”); ﬂail limb (n=10) and progressive muscular atrophy
(n=12), merged to form the group lower motor neuron variants
(“LMN”); ALS with comorbid frontotemporal dementia (n=13, “ALS-
FTD”). All patients were classiﬁed according to the revised El-Escorial
criteria (Brooks et al., 2000) and physical disability was rated using the
ALS functional rating scale revised (ALSFRS-R) (Cedarbaum et al.,
1999). A concomitant diagnosis of frontotemporal dementia (FTD) was
deﬁned on clinical assessment in accordance with proposed diagnostic
criteria and included interview of the accompanying caregiver. n=12
patients fulﬁlled criteria for behavioural variant FTD (bvFTD)
(Rascovsky et al., 2011); and n=1 patient for non-ﬂuent primary
progressive aphasia (nfPPA) (Gorno-Tempini et al., 2011). Genetic
testing was performed, looking for mutations in the superoxide dis-
mutase 1 protein (SOD1), chromosome 9 open reading frame 72 protein
(C9orf72), TAR DNA-binding protein 43 (TARBDP), ubiquilin protein
(UBQLN), and RNA-binding protein fused in sarcoma (FUS). The iden-
tiﬁed genetic cases (n=16) are listed in Table 1 and highlighted in
Figs. 2 and 3. A general score of cognition was obtained using the
Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005),
which was additionally adjusted in the patient cohort to control for
motor disability (i.e. excluding subtests 1–3 from the general scoring).
A group of 86 healthy controls was recruited (site 1: n=47; site 2:
n=39) and clinically screened to exclude neurological illness and
cognitive impairment (MoCA score≥ 26). To assess general educa-
tional level, all participants completed a German version of the voca-
bulary test (WST) (Schmidt and Metzler, 1992). Demographic data of
all participants are summarised in Table 1.
All participants underwent a detailed neuropsychological assess-
ment, testing the domains of executive function, verbal memory, be-
haviour, and visuo-spatial skills. In order to make sure that cognitive
impairment does not confound the data analysis, patients' performance
on the following tests was utilised for additional classiﬁcation into MND
with cognitive impairment (MND-ci), MND with behavioural impair-
ment (MND-bi), and MND with combined cognitive and behavioural
impairment (MND-cbi) according to the revised Strong criteria (Strong
et al., 2017): Letter ﬂuency and ﬂexibility indices, semantic ﬂuency and
ﬂexibility indices, trail making test (TMT), Stroop test, backward digit
span, and the apathy scale from the Frontal Systems Behaviour Scale
(FrSBe). Patients were classiﬁed as MND-ci if they showed impairment
in verbal ﬂuency and/or ﬂexibility or impairment on two other in-
dependent executive functions. Impairment was deﬁned as scoring
below 2 SD of the performance of the healthy controls in the corre-
sponding test. To be categorised as MND-bi, patients had to be impaired
in the apathy scale of the FrSBe. If patients fulﬁlled criteria for both
MND-ci and MND-bi they were classiﬁed as MND-cbi. Out of 158 pa-
tients, n=25 could not be classiﬁed due to missing neuropsychological
assessment. Means and standard deviations of neuropsychological data
are displayed in Supplementary Table 1.
The local ethics committees of both universities approved the study
and all subjects gave written informed consent prior to their inclusion.
2.2. Data acquisition and analysis
High-resolution, T1-weighted structural MRI scans were acquired at
both study sites using 3 T Siemens VERIO Magnetom scanners
(Siemens, Erlangen/Germany) with an identical acquisition protocol
that employed a 32-channel head coil and a 3D-MPRAGE sequence
(echo time=4.82ms, repetition time=2500ms, inversion
Table 1
Demographic proﬁle of participants.
HC MND p value Classical ALS PLS UMN LMN ALS-FTD p value
No. 86 158 102 9 13 21 13
Median age (range) 62.3 (33–83) 61.3 (32–83) 0.668c 60.3 (32–83) 62.7 (53–71) 57.3 (35–69) 64.6 (40–79) 66.7 (40–75) 0.087b
Sex [male (%)] 54 (62.8%) 98 (62.0%) 0.906a 61 (59.8%) 6 (66.7%) 9 (69.2%) 16 (76.2%) 6 (46.2%) 0.439a
Handedness [right (%)] 78 (90.7%) 149 (94.3%) 0.291a 96 (94.1%) 9 (100%) 13 (100%) 19 (90.5%) 12 (92.3%) 0.736a
Median ALSFRS-R
(range)
– 39.0 (14–48) – 39.0 (14–48) 36.0 (28–41) 38.0 (30–44) 41.0 (26–46) 41.0 (22–46) 0.060b
Median disease duration
[months] (range)
– 16.6 (3.6–272.3) – 15.8
(3.6–104.8)
93.4
(13.9–272.3)
11.7
(4.1–67.4)
18.6
(4.0–100.9)
15.1
(6.3–127.8)
0.003b
El Escorial (NA/possible/
probable/deﬁnite)
23/44/32/59 4/22/25/51 0/8/1/0 0/8/1/4 17/3/1/0 2/3/4/4 –
SOD1 mutation (%) – 5 (3.2%) – 4 (3.9%) 0 (0%) 0 (0%) 1 (4.8%) 0 (0%) –
C9orf72 repeat expansion
(%)
– 11 (7.0%) – 10 (9.8%) 0 (0%) 0 (0%) 0 (0%) 1 (7.7%) –
Median WST (range) 32.0 (26–40);
n=71
30.0 (14–41);
n=126
<0.001c 31.0 (14–41) 31.0 (18–39) 30.5 (15–33) 28.0 (18–35) 27.0 (17–37) 0.316b
Median MoCA (range) 27.0 (26–30);
n=86
25.5 (9–30);
n=150
<0.001c 25.5 (12−30) 26.0 (21−30) 25.5 (18–30) 25.0 (21–30) 18.5 (9–24) < 0.001b
HC: healthy controls; MND: motor neuron disease; PLS: primary lateral sclerosis; UMN: upper motor neuron variants; LMN: lower motor neuron variants; ALS-FTD: ALS with comorbid
frontotemporal dementia; ALSFRS-R: ALS Functional Rating Scale revised (Cedarbaum et al., 1999); MoCA: Montreal Cognitive Assessment (Nasreddine et al., 2005).
a Based on Pearson's χ2.
b Based on Kruskal-Wallis χ2.
c Based on Wilcoxon U.
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time=1100ms, ﬂip angle= 7°, voxel size= 1×1×1mm3). Prior to
this study, basic quality assurance tests were carried out using the
American College of Radiation (ACR) phantom at both sites with no
signiﬁcant diﬀerences in the tested parameters. Data were analysed
using FreeSurfer (Fischl, 2012) version 5.3.0 (http://surfer.nmr.mgh.
harvard.edu/). Regional measures of cortical thickness were obtained
from the automated anatomic parcellation (Desikan et al., 2006).
Brieﬂy, standardised preprocessing steps included intensity normal-
isation, skull stripping, Talairach transformation, and assignment of
neuroanatomical labels to each voxel using the Desikan-Killiany prob-
abilistic atlas (Desikan et al., 2006), resulting in 34 distinct cortical
regions for each hemisphere. The obtained cortical segmentations were
inspected for errors and no manual editing was necessary. The focus of
the study was the prefrontal cortex, therefore we created a region of
interest (ROI) of the prefrontal cortex by merging the following De-
sikan-Killiany regions of each hemisphere separately using mri_merge-
labels as implemented in freesurfer: superior frontal gyrus, middle
frontal gyrus (rostral division), inferior frontal gyrus (pars opercularis,
pars orbitalis, pars triangularis), orbitofrontal cortex (lateral and
medial division), frontal pole, and the anterior cingulate cortex (rostral
and caudal division). Note that primary motor and premotor regions
were not included in the prefrontal ROI. In order to demonstrate dif-
ferences between motor and prefrontal regions, the caudal part of the
bilateral middle frontal gyrus served as a ROI of the premotor cortex,
whereas the bilateral precentral gyrus served as the ROI of the primary
motor cortex. The occipital lobe was included as an additional ROI, as it
is known to be the least aﬀected cortical region by the ongoing motor
degeneration, and therefore served as a reference region. It included the
following Desikan-Killiany regions: lingual gyrus, pericalcerine cortex,
cuneus cortex, and lateral occipital cortex. These regions were, similiar
to the prefrontal ROI, merged using mri_mergelabels as implemented in
FreeSurfer. Mean thickness values for the selected ROIs were obtained
separately for each hemisphere and adjusted for age using the covar-
iance method (Jack et al., 1989). No adjustment was done for the total
intracranial volume (TIV) as it has been shown to be not related to
cortical thickness (Barnes et al., 2010).
The distribution of cortical thickness values and demographic data
was tested for normality of distribution using Shapiro-Wilk tests.
Demographic variables were not normally distributed and diﬀerences
between groups were assessed using chi-square (gender, handedness)
and Kruskal-Wallis (age, WST, MoCA) or Wilcoxon tests (for group
comparisons HC/MND). Diﬀerences in cortical thickness in each of the
a priori deﬁned ROIs were assessed for each hemisphere separately,
conducting ﬁxed eﬀects models with group (HC/MND) and gender as
ﬁxed factors. In order to test a possible eﬀect of scanning location, a
random eﬀect was added in a basic model (predicting cortical thickness
values only by the intercept) by allowing the intercepts to vary across
sites. For both models, the Akaike information criterion (AIC), Schwarz
Bayesian criterion (BIC), and the log-likelihood of the chi-square like-
lihood ratio test were compared. Adding the scanning location did not
improve the ﬁt of the model (indicated by smaller AIC, BIC, and log-
likelihood values) and was therefore not further considered in the
analysis (Supplementary Table 2).
The statistical signiﬁcance threshold was set to p=0.006 (0.05/8)
following Bonferroni correction to account for multiple comparison of 8
ROIs. Additionally, patients' and controls' cortical thickness values were
Z-standardised by healthy control mean and standard deviation (SD) in
each of the four ROIs to identify cases lying worse than −1 SD below
healthy control mean using chi-square tests to assess diﬀerences in
proportions between MND and HC.
In order to identify cortical thickness diﬀerences between clinical
phenotypes, ﬁxed eﬀects models with phenotype (classical ALS/PLS/
UMN/LMN) and gender as ﬁxed factors were conducted. Note that ALS-
FTD patients were excluded from this analysis to explore diﬀerences in
thickness between varying degrees of upper and lower motor neuron
involvement alone. The impact of cognitive and behavioural deﬁcits on
cortical thickness was tested using ﬁxed eﬀects models with cognitive
phenotype (MND/MNDci, MNDbi, MND cbi/ALS-FTD) and gender as
ﬁxed factors. In case of a signiﬁcant group eﬀect, post hoc tests were
performed by pairwise comparisons using t-tests with pooled standard
deviation and results were corrected for multiple comparisons (false
discovery rate (FDR); p < 0.05 was considered signiﬁcant).
Spearman rank correlations were computed to determine the re-
lationship between mean cortical thickness in all four ROIs and not-
normally distributed clinical parameters, i.e. physical disability
(ALSFRS-R), disease duration, and general cognitive ability (MoCA)
with the signiﬁcance level adjusted to p=0.017 (0.05/3) following
Bonferroni correction. The statistical analysis was done using R version
3.4.3.
3. Results
3.1. Group comparisons
Age-adjusted mean cortical thickness values in the left (HC:
W=0.99, p=0.91; MND: W=0.98, p=0.02) and right (HC:
W=0.98, p=0.12; MND: W=0.99, p=0.19) premotor, as well as in
the left (HC: W=0.99, p=0.84; MND: W=0.98, p=0.06) and right
(HC: W=0.99, p=0.76; MND: W=0.99, p=0.26) prefrontal and
occipital (left HC:W=0.98, p=0.18; MND:W=0.99, p=0.34; right
HC: W=0.98, p=0.19; MND: W=0.99, p=0.54) cortices were
normally distributed in patients and controls (Fig. 1). Shapiro-Wilk test
indicated a signiﬁcant deviation of the left (HC: W=0.99, p=0.79;
MND:W=0.96, p=0.003) and right (HC:W=0.95, p=0.004; MND:
W=0.98, p=0.02) motor cortex thickness from the normal distribu-
tion in the patient cohort (and healthy controls for the left motor
cortex), but inspection of the quantile-quantile (QQ) plots (Supple-
mentary Fig. 1) and histograms (Fig. 1) did not show a major deviance.
Cortical thickness of the right (p=0.002) motor cortex was sig-
niﬁcantly reduced in MND patients when compared to controls.
Diﬀerences in left motor thickness did not reach the predetermined
signiﬁcance level (p=0.007). Removing those patients with comorbid
FTD (right: p=0.004, left: p=0.02) did not change these eﬀects, as it
was the case when removing those cases carrying a C9orf72 gene mu-
tation (right: p=0.004, left: p=0.01). No between-group diﬀerences
were found for the left (p=0.03) and right prefrontal cortex
(p=0.23). There was no MND-related thinning in the premotor cortex
(left: p=0.31, right: p=0.13) or occipital cortex (left: p=0.31, right:
p=0.16). Means, standard deviations, and F values are summarised in
Table 3.
Fig. 2 illustrates the distribution of mean cortical thickness values in
patients when standardised to z-scores. In a normal distribution, 15.9%
of cases are expected to fall outside −1 standard deviation. The pro-
portion of MND patients falling outside −1 standard deviation of the
control distribution was signiﬁcantly increased for the right (29.1%,
p=0.002) motor cortical thickness (Table 2). A similar proﬁle, al-
though not reaching the signiﬁcance level of p=0.006, was observed
for the left motor cortex (28.5%), right premotor cortex (27.8%), and
left prefrontal cortex (26.6%) of MND cases lay worse than−1 SD from
the healthy control mean, respectively, indicating that the patient co-
hort was shifted towards the left side of the control normal distribution.
This was not the case for the occipital cortex.
3.2. Clinical phenotypes
There were no phenotype-related diﬀerences in cortical thickness
values in the premotor, occipital, or prefrontal cortices (Table 3).
Thinning of the left motor cortex was a function of clinical phenotype
(F=2.63, p=0.014 (FDR-corrected)) in that PLS patients had worse
cortical thinning than classical ALS patients and LMN variants (Sup-
plementary Fig. 2).
With regard to cognitive phenotype (MND/MND-ci, MND-bi, MND-
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cbi/ALS-FTD), MND patients with cognitive and/or behavioural im-
pairment compared to MND patients with no cognitive impairment had
signiﬁcantly thinner left motor and prefrontal cortices (Table 3). The
distribution of z-standardised thickness values for the C9orf72 mutation
carrier was comparable to the one of MND and MND-ci/bi patients,
with exception of the right motor cortex, where distribution was similar
to that of ALS-FTD patients, and the right occipital cortex (Supple-
mentary Fig. 3).
3.3. Clinical correlations
Thinning of the left motor cortex was associated with lower
ALSFRS-R scores (ρ=0.22, p=0.006) but not with disease duration
(ρ=−0.18, p=0.022). Cortical thickness values in the premotor, as
well as in the prefrontal and occipital cortices were not associated with
either physical disability or disease duration.
There was a signiﬁcant relationship between patients' MoCA per-
formance and prefrontal cortical thickness (left: ρ=0.34, p < 0.001;
right: ρ=0.28, p < 0.001). This stayed signiﬁcant when controlling
the MoCA for motor impairment (left: ρ=0.32, p < 0.001; right:
ρ=0.27, p=0.001). A similar relationship was observed between
patients' MoCA performance and thickness of the motor (left: ρ=0.35,
p < 0.001; right: ρ=0.34, p < 0.001) and premotor cortices (left:
ρ=0.33, p < 0.001; right: ρ=0.24, p=0.003) (Fig. 3). Thickness of
the left occipital cortex was also associated with patients' MoCA per-
formance, although to a lower degree (ρ=0.24, p=0.003).
After removing those patients with comorbid FTD, the relationship
between MoCA performance and motor cortical thickness remained
signiﬁcant (left: ρ=0.22, p=0.009; right: ρ=0.24, p=0.004). A si-
milar relationship was found when removing C9orf72 mutation carriers
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Fig. 1. Normal distribution (main diagonal) and inter-correlation (above the diagonal: Pearson correlation coeﬃcients for MND (blue) and HC (red); below the diagonal: correlation
scatterplots) of age-adjusted mean cortical thickness values (mm) for the motor cortex, premotor cortex, prefrontal cortex, and occipital cortex in healthy controls (red) and MND patients
(blue). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(left: ρ=0.22, p=0.009; right: ρ=0.24, p=0.004). This was not the
case for the premotor (left: ρ=0.13, p=0.122; right: ρ=0.08,
p=0.325), prefrontal (left: ρ=0.18, p=0.036; right: ρ=0.14,
p=0.092), and occipital cortices (left: ρ=0.14, p=0.103; right:
ρ=0.06, p=0.509). There was no relationship between healthy con-
trols' MoCA performance and cortical thickness of the motor and pre-
motor as well as the occipital and prefrontal cortices.
4. Discussion
The results of this prospective, cross-sectional study indicate an
increased prevalence of prefrontal cortical thinning in patients with
motor neuron disease and cognitive or behavioural deﬁcits. Our data
indicate that the distribution of prefrontal thickness was unimodal and
independent of motor neuron disease phenotype, disease duration or
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Fig. 2. Distribution of age-adjusted, z-standardised mean cortical thickness values for left and right motor cortex, premotor cortex, prefrontal cortex, and occipital cortex for classical ALS
(black), PLS (yellow), UMN (blue), LMN (green), and ALS-FTD (red). Crosses indicate C9orf72 repeat expansion carriers (+), and triangles indicate SOD1 mutation carriers (Δ). Unﬁlled
symbols indicate patients with comorbid cognitive (MND-ci) or behavioural (MND-bi) impairment. Z-values are standardised by healthy control mean and standard deviation. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Incidence of cases lying 1 SD below/above healthy control mean cortical thicknessa.
Cortical thickness MND
<M−1SD (%)
HC
<M−1SD (%)
χ2 p value MND
>M+1SD (%)
HC
>M+1SD (%)
χ2 p value
Motor cortex Left 45 (28.5%) 15 (17.4%) 3.66 0.06 17 (10.8%) 12 (14.0%) 0.54 0.46
Right 46 (29.1%) 10 (11.6%) 9.63 0.002 8 (5.1%) 9 (10.5%) 2.51 0.11
Premotor cortex Left 34 (21.5%) 16 (18.6%) 0.29 0.59 27 (17.1%) 14 (16.3%) 0.03 0.87
Right 44 (27.8%) 16 (18.6%) 2.57 0.12 20 (12.7%) 10 (11.6%) 0.05 0.82
Prefrontal cortex Left 42 (26.6%) 16 (18.6%) 1.96 0.16 18 (11.4%) 15 (17.4%) 1.74 0.19
Right 31(19.6%) 15 (17.4%) 0.17 0.68 17 (10.8%) 15 (17.4%) 2.18 0.14
Occipital cortex Left 27 (17.1%) 12 (14.0%) 0.41 0.52 19 (12.0%) 16 (18.6%) 1.96 0.16
Right 35 (22.2%) 12 (14.0%) 2.41 0.12 18 (11.4%) 12 (14.0%) 0.34 0.56
M: mean of the healthy controls; SD: standard deviation.
Signiﬁcant values are shown in bold (p≤ 0.006, following Bonferroni correction).
a In a normal distribution, 15.9% of cases are expected to fall outside± 1 SD, 6.7% outside ± 1.5 SD, and 2.5% outside ± 2 SD.
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severity, but associated with cognitive or behavioural impairment.
MND-related thinning was observed in the right motor cortex,
whereas thickness in the prefrontal, premotor, and occipital cortex did
not diﬀer between groups when subgroups were not considered.
Diﬀerences in motor cortical thickness remained signiﬁcant even after
removing those patients with comorbid FTD and C9orf72 mutation
carriers, indicating that motor cortical thickness is reduced throughout
the MND spectrum. Although cortical thickness values were normally
distributed, the proportion of MND cases lying worse than −1 SD
below the control mean in the right motor cortex was signiﬁcantly
higher than would be expected by chance, indicating a shift of dis-
tribution towards thinner cortex in this region (Table 2). A similar
pattern was observed in the left motor, left prefrontal, and right pre-
motor cortex, although not reaching the predetermined signiﬁcance
level.
Thinning of the left motor cortex tended to be a function of clinical
phenotype in that PLS variants had worse cortical thinning than clas-
sical ALS patients and LMN variants. This is in line with recent studies
on cortical thickness in the motor cortex, where thinning is reported to
be highest in UMN variants (of which PLS presents an extreme), fol-
lowed by classical ALS, while pure LMN variants do not diﬀer from
disease mimics (Walhout et al., 2015b) and healthy controls (Schuster
et al., 2013). Notably, this phenotype speciﬁc pattern was not observed
in the premotor, prefrontal, and occipital cortices.
When segregating the MND patients based on their cognitive per-
formance, a signiﬁcant shift towards thinner motor and prefrontal
cortices was identiﬁed in patients with cognitive and/or behavioural
impairment when compared to MND patients without cognitive dys-
function. Although left prefrontal thickness values diﬀered between
these groups, the overlaying kernel density estimations (Supplementary
Fig. 3) showed a similar distribution while shifted towards thinner
cortex in MND with cognitive impairment, as it was the case for ALS
patients with comorbid FTD. This was supported by the fact that ALS
patients with comorbid FTD were more likely to be worse than −1 SD
in the prefrontal cortex, but not all of them showed prefrontal cortical
thinning. The majority of ALS-FTD patients included in this study (12
out of 13) fulﬁlled the criteria for bvFTD (Rascovsky et al., 2011),
where behavioural changes are the hallmark of the disease and pre-
frontal cortical atrophy is a common feature. Nevertheless, hetero-
geneity in atrophy patterns across bvFTD is high and can depend on
patients' behavioural proﬁle (Massimo et al., 2009; Walhout et al.,
2015a), genotype (Whitwell et al., 2012), or subtype (Whitwell et al.,
2009). Within this scenario, it could also be possible, that a lot of dif-
ferent subtypes within the established phenotypes led to the relatively
uniform distribution. Further studies with larger sample sizes ac-
counting for the large heterogeneity in phenotypes have to be con-
ducted in order to exclude this possible confound.
The identiﬁed thinning of the prefrontal and motor cortex was
speciﬁc for MND with cognitive and/or behavioural impairment in that
no cortical thinning was observed in the occipital control region or the
premotor cortices, showing that the observed thinning is not indicative
of a global atrophy process. The occipital lobe was thought to be re-
latively spared from the ongoing neurodegeneration associated with
MND, but recent studies show that especially C9orf72 mutation carrier
can show involvement of occipital regions in symptomatic (Westeneng
et al., 2016) and even asymptomatic disease stages (Walhout et al.,
2015a). Interestingly, although the numbers are too small to draw any
further conclusions, our results indicate a shift towards thinner right
occipital cortex for the included C9orf72 population but not for MND,
MND with cognitive/behavioural deﬁcits, or even ALS-FTD (Supple-
mentary Fig. 3).
The clinical impact of frontal lobe thinning is further highlighted by
the identiﬁed relationship between cortical thinning in the bilateral
prefrontal, premotor, and motor areas and patients' general cognitive
abilities. Although it is now recognised that frontal lobe dysfunction in
MND encompasses more than executive dysfunction (Abrahams, 2013;
Table 3
Means and standard deviations of cortical thickness values for diﬀerent clinical phenotypes.
Motor cortical thickness Premotor cortical thickness Prefrontal cortical thickness Occipital cortical thickness
Left Right Left Right Left Right Left Right
HC 2.50 ± 0.15 2.40 ± 0.16 2.44 ± 0.13 2.42 ± 0.14 2.46 ± 0.09 2.39 ± 0.09 1.92 ± 0.11 1.96 ± 0.10
MND 2.43 ± 0.18 2.33 ± 0.17 2.41 ± 0.16 2.38 ± 0.15 2.43 ± 0.11 2.37 ± 0.10 1.91 ± 0.10 1.94 ± 0.11
F 5.03 6.57 1.81 2.08 3.69 1.47 1.17 1.87
p 0.007 0.002 0.309 0.128 0.026 0.232 0.311 0.156
class. ALS 2.46 ± 0.15 2.35 ± 0.16 2.43 ± 0.14 2.40 ± 0.14 2.44 ± 0.10 2.38 ± 0.09 1.91 ± 0.10 1.94 ± 0.11
PLS 2.30 ± 0.22 2.27 ± 0.14 2.37 ± 0.17 2.38 ± 0.14 2.43 ± 0.09 2.36 ± 0.09 1.90 ± 0.13 1.94 ± 0.17
UMN 2.36 ± 0.21 2.30 ± 0.19 2.39 ± 0.16 2.39 ± 0.12 2.40 ± 0.13 2.38 ± 0.10 1.94 ± 0.11 1.96 ± 0.10
LMN 2.47 ± 0.14 2.35 ± 0.13 2.45 ± 0.15 2.40 ± 0.15 2.45 ± 0.09 2.37 ± 0.08 1.94 ± 0.08 1.97 ± 0.10
F 3.88 2.21 1.14 1.19 0.95 0.40 1.80 1.86
p 0.005 0.071 0.338 0.317 0.440 0.808 0.132 0.122
ALS vs. PLS
p=0.032
LMN vs. PLS
p=0.032
MND 2.46 ± 0.17 2.35 ± 0.16 2.44 ± 0.15 2.41 ± 0.02 2.45 ± 0.10 2.39 ± 0.09 1.92 ± 0.10 1.95 ± 0.11
MNDci/bi 2.40 ± 0.15 2.31 ± 0.07 2.39 ± 0.11 2.36 ± 0.14 2.41 ± 0.10 2.36 ± 0.09 1.90 ± 0.07 1.94 ± 0.09
ALS-FTD 2.26 ± 0.19 2.17 ± 0.17 2.21 ± 0.17 2.22 ± 0.14 2.28 ± 0.14 2.26 ± 0.13 1.86 ± 0.11 1.91 ± 0.09
F 6.65 6.55 9.98 8.53 11.32 8.08 2.28 1.57
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.081 0.199
MND vs. MNDci/bi
p=0.042
MNDci/bi vs. ALS-
FTD p=0.016
MND vs. ALS-FTD
p≤0.001
MNDci/bi vs.
ALS-FTD
p=0.009
MND vs. ALS-FTD
p≤0.001
MNDci/bi vs. ALS-
FTD p≤0.001
MND vs. ALS-FTD
p≤0.001
MNDci/bi vs. ALS-
FTD p=0.004
MND vs. ALS-FTD
p≤0.001
MND vs. MNDci/bi
p=0.048
MNDci/bi vs. ALS-
FTD p < 0.001
MND vs. ALS-FTD
p≤0.001
MNDci/bi vs. ALS-
FTD p=0.002
MND vs. ALS-FTD
p≤0.001
Signiﬁcant values are shown in bold (p≤ 0.006, following Bonferroni correction).
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Canu et al., 2013; Raaphorst et al., 2011), the MoCA as a measure of
general cognitive impairment seems to be a valid instrument to map
these changes. Interestingly, it was not only associated with prefrontal
lobe thinning but also premotor and motor thinning in the patient co-
hort. Movement and cognition are closely interrelated, and the pre-
motor cortex, in particular, plays an important role in mediating input
information from the prefrontal cortex to the motor cortex (Dum and
Strick, 1991). Therefore, it is not surprising that thinning in all of these
regions was related to the patients' decline in general cognitive abilities.
This relationship was not observed in the healthy control group, al-
though it must be considered that, according to the inclusion criteria,
they were not allowed to score below the cut-oﬀ of 26 points in the
MoCA, resulting in a rather small range within this group that could
have biased the results.
In summary, this study demonstrated that the prevalence of pre-
frontal cortical thinning is increased in MND phenotypes and related to
patients' general cognitive ability. Prefrontal cortical thickness was
normally distributed in MND but shifted towards thinner cortex in MND
with cognitive and/or behavioural impairment compared to MND pa-
tients without cognitive impairment, suggesting a more general vul-
nerability to FTD for this group. There was also evidence that, with
primary motor and premotor regions omitted, prefrontal cortical
thinning is independent of the degree of upper and lower motor neuron
involvement, disease duration, and physical disability, but related to
cognitive dysfunction.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2018.03.002.
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